<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01640808</url>
  </required_header>
  <id_info>
    <org_study_id>NIK-333-05</org_study_id>
    <nct_id>NCT01640808</nct_id>
  </id_info>
  <brief_title>Study of Peretinoin for Suppressing Recurrence of HCV-positive HCC</brief_title>
  <official_title>NIK-333(Peretinoin) PhaseⅢ Study Investigation of the Efficacy and Safety to Suppress Recurrence of Hepatitis C Virus(HCV)-Positive Hepatocellular Carcinoma(HCC), Multicenter, Randomised, Double-blind, Placebo-controlled, Parallel-group Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kowa Company, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kowa Company, Ltd.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to verify the superiority of NIK-333 (Peretinoin) to placebo in&#xD;
      inhibiting the recurrence of HCV-positive HCC in patients showing complete cure of the&#xD;
      disease, with the recurrence-free survival as the primary endpoint, in a multi-center,&#xD;
      randomized, double-blind, placebo-controlled, parallel-group comparison study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2012</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence-free Survival</measure>
    <time_frame>Date of randomization to the date of recurrence of HCC (followed every 12 weeks) or death (whichever occurs first)</time_frame>
    <description>HCC recurrence was defined as the appearance of new intrahepatic lesions which was confirmed based on findings of hypervascularity (nodules enhanced in the arterial phase and washout in the late phase) by dynamic CT images, or a new extrahepatic metastasis. Recurrence of intrahepatic HCC was evaluated by an independent image reading committee.&#xD;
RFS was defined as the time from randomization to HCC recurrence or death from any cause, whichever occurred first. For subjects who terminated the study without HCC recurrence or death, RFS was censored at the day of the latest dynamic CT examination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free Survival</measure>
    <time_frame>Date of randomization to the date of recurrence of HCC (followed every 12 weeks), death, or secondary cancer (malignant tumors other than HCC)(whichever occurs first)</time_frame>
    <description>DFS was defined as the time from randomization to HCC recurrence, death from any cause or occurrence of secondary cancer (malignant tumors other than HCC), whichever occurred first. For subjects who terminated the study without HCC recurrence, death, or occurrence of secondary cancer, DFS was censored at the day of the latest dynamic CT examination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Recurrence</measure>
    <time_frame>Date of randomization to the date of recurrence of HCC(followed every 12 weeks)</time_frame>
    <description>TTR was defined as the time from randomization to HCC recurrence. For subjects who terminated the study without HCC recurrence, TTR was censored at the day of the latest dynamic CT examination.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">616</enrollment>
  <condition>Hepatic Neoplasm Malignant Recurrent</condition>
  <arm_group>
    <arm_group_label>NIK-333(peretinoin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NIK-333(peretinoin)</intervention_name>
    <description>600mg (8 x 75mg capsules) orally, twice a day</description>
    <arm_group_label>NIK-333(peretinoin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (8 x Placebo capsules) orally, twice a day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with HCV-positive HCC who meet the following conditions before radical&#xD;
             treatment&#xD;
&#xD;
               -  Patients diagnosed as having typical HCC on dynamic CT,CTA/CTAP, or dynamic MRI&#xD;
                  (nodule visualized as a high signal intensity area in the arterial phase and as a&#xD;
                  relatively low signal intensity area in the portal and equilibrium phases)&#xD;
                  performed within 8 weeks (56 days) before treatment start prior to radical&#xD;
                  therapy&#xD;
&#xD;
               -  Patients with the first primary HCC or the first recurrence of primary HCC&#xD;
&#xD;
          2. Patients who received the radical therapies. The treatment duration (from the start to&#xD;
             the end of the treatment) should be within 4 weeks (28 days) for each of the radical&#xD;
             therapies.&#xD;
&#xD;
          3. Patients showing a complete cure, as confirmed by the dynamic CT images taken from 8&#xD;
             weeks (56 days) to 12 weeks (84 days) after the end of the treatment show a&#xD;
             non-stained low-concentration area overlapping the tumor image observed before&#xD;
             complete cure.&#xD;
&#xD;
          4. Patients who are able to begin treatment with the study drug within 8 weeks (56 days)&#xD;
             after dynamic CT to confirm complete cure&#xD;
&#xD;
          5. Patients confirmed of satisfying the following conditions based on the screening&#xD;
             performed at subject registration&#xD;
&#xD;
               -  Positive for serum hepatitis C virus nucleic acid (HCV-RNA)&#xD;
&#xD;
               -  Grade A on Child-Pugh classification&#xD;
&#xD;
               -  Platelet count of 50 000/µL or higher&#xD;
&#xD;
          6. Patients with ECOG Performance Status score of 0 to 1&#xD;
&#xD;
          7. Patients of the age of 20 years or older at the time of informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients positive for HBs antigen&#xD;
&#xD;
          2. Patients showing vascular invasion of HCC on imaging diagnosis&#xD;
&#xD;
          3. Patients who have also undergone transcatheter arterial embolization therapy&#xD;
             (TAE/TACE), transarterial infusion therapy (TAI), and chemolipiodolization in&#xD;
             combination with the radical therapy&#xD;
&#xD;
          4. 4 Patients who want to receive antiviral therapy such as concomitant therapy with&#xD;
             intaferon during the study period&#xD;
&#xD;
          5. Patients who have received other study drugs, anticancer drugs, or interferons after&#xD;
             radical therapy&#xD;
&#xD;
          6. Patients who have hypertension as a complication, and whose blood pressure cannot be&#xD;
             controlled by drug therapy (systolic blood pressure of 160 mmHg or higher or diastolic&#xD;
             blood pressure of 100 mmHg or higher, as determined at subject registration)&#xD;
&#xD;
          7. Patients who have a history of allergy to CT contrast media, and whose participation&#xD;
             in this study is judged to be inappropriate by the investigator or the subinvestigator&#xD;
&#xD;
          8. Patients with a history of total gastrectomy&#xD;
&#xD;
          9. Patients with a history of cardiac arrest&#xD;
&#xD;
         10. Patients with any of the following laboratory values or complications&#xD;
&#xD;
               -  Creatinine&gt;= 1.5mg/dL&#xD;
&#xD;
               -  Albumin urine &gt;= 1000mg/g Creatinine&#xD;
&#xD;
               -  Cardiac disorder corresponding to CTC-AE grade 3 in severity&#xD;
&#xD;
               -  HbA1c &gt;= 7.4 under treatment with insulin&#xD;
&#xD;
               -  Autoimmune disease or asthma being treated with oral steroid&#xD;
&#xD;
         11. Patients confirmed of having another malignant neoplasm or who had undergone a radical&#xD;
             therapy of HCC within the past 5 years to treat another malignant neoplasm (however,&#xD;
             this does not apply to endoscopic resection and resection of intraepithelial&#xD;
             carcinoma)&#xD;
&#xD;
         12. Patients who are pregnant, who have a possibility of being pregnant or who have a&#xD;
             desire to become pregnant during the study period&#xD;
&#xD;
         13. Lactating women&#xD;
&#xD;
         14. Patients who have a history of allergy to retinoid-related substances (vitamin A,&#xD;
             etc.) in the past&#xD;
&#xD;
         15. Patients who participated in another clinical study within past 6 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>466-0065</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>467-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Matsuyama</city>
        <state>Ehime</state>
        <zip>790-0826</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iizuka</city>
        <state>Fukuoka</state>
        <zip>820-0018</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kurume</city>
        <state>Fukuoka</state>
        <zip>830-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ogaki</city>
        <state>Gifu</state>
        <zip>503-0864</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>006-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-0033</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Himeji</city>
        <state>Hyogo</state>
        <zip>670-0063</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <zip>650-0047</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nishinomiya</city>
        <state>Hyogo</state>
        <zip>663-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kanazawa</city>
        <state>Ishikawa</state>
        <zip>920-8641</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kawasaki</city>
        <state>Kanagawa</state>
        <zip>213-8587</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sagamihara</city>
        <state>Kanagawa</state>
        <zip>228-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sagamihara</city>
        <state>Kanagawa</state>
        <zip>252-0375</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>232-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>241-0815</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nankoku</city>
        <state>Kochi</state>
        <zip>783-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kurashiki</city>
        <state>Okayama</state>
        <zip>701-0192</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ikeda</city>
        <state>Osaka</state>
        <zip>563-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moriguchi</city>
        <state>Osaka</state>
        <zip>570-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osakasayama</city>
        <state>Osaka</state>
        <zip>589-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sakai</city>
        <state>Osaka</state>
        <zip>591-8025</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iruma</city>
        <state>Saitama</state>
        <zip>350-0495</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sunto-gun</city>
        <state>Shizuoka</state>
        <zip>411-8777</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shimotsuke</city>
        <state>Tochigi</state>
        <zip>329-0498</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Musashino</city>
        <state>Tokyo,</state>
        <zip>180-8610</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bunkyo-ku,</city>
        <state>Tokyo</state>
        <zip>113-8519</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8655</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chiyoda-ku</city>
        <state>Tokyo</state>
        <zip>101-8643</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <zip>105-8470</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ota-ku</city>
        <state>Tokyo</state>
        <zip>143-8541</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Setagaya-ku</city>
        <state>Tokyo</state>
        <zip>158-8531</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shibuya-ku</city>
        <state>Tokyo</state>
        <zip>150-8935</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shimonoseki</city>
        <state>Yamaguchi</state>
        <zip>750-0061</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ube</city>
        <state>Yamaguchi</state>
        <zip>755-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kofu</city>
        <state>Yamanashi</state>
        <zip>400-8506</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chiba</city>
        <zip>260-0856</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukuoka</city>
        <zip>810-8563</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukuoka</city>
        <zip>814-0180</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gifu</city>
        <zip>500-8513</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gifu</city>
        <zip>501-1194</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hiroshima</city>
        <zip>734-8530</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hiroshima</city>
        <zip>734-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kagoshima</city>
        <zip>890-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kumamoto</city>
        <zip>860-0811</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagasaki</city>
        <zip>852-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Niigata</city>
        <zip>950-1104</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oita</city>
        <zip>879-5593</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Okayama</city>
        <zip>700-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osaka</city>
        <zip>534-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osaka</city>
        <zip>537-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osaka</city>
        <zip>540-0006</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osaka</city>
        <zip>543-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osaka</city>
        <zip>545-8586</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saga</city>
        <zip>840-8571</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saga</city>
        <zip>849-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokushima</city>
        <zip>770-8503</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokushima</city>
        <zip>770-8539</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wakayama</city>
        <zip>641-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>July 10, 2012</study_first_submitted>
  <study_first_submitted_qc>July 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2012</study_first_posted>
  <results_first_submitted>June 1, 2020</results_first_submitted>
  <results_first_submitted_qc>November 29, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 2, 2020</results_first_posted>
  <last_update_submitted>November 29, 2020</last_update_submitted>
  <last_update_submitted_qc>November 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Screened:778 Enrolled:616 Received treatment:610</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>NIK-333(Peretinoin)</title>
          <description>NIK-333(peretinoin): 600mg (8 x 75mg capsules) orally, twice a day</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo: Placebo (8 x Placebo capsules) orally, twice a day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="309"/>
                <participants group_id="P2" count="307"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Subjects Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="305"/>
                <participants group_id="P2" count="305"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="251"/>
                <participants group_id="P2" count="291"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Unable to continue dynamic CT</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Start an antiviral therapy using IFN</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administration of anticancer drugs</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized but not treated</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full analysis set (FAS) consisted of 605 subjects among 616 randomized subjects. Reasons for 11 excluded subjects are as following;&#xD;
6 Subjects (NIK-333 group: 4, Placebo group: 2) who did not take any study drugs&#xD;
5 Subjects (NIK-333 group: 4, Placebo group: 1) who had no efficacy data</population>
      <group_list>
        <group group_id="B1">
          <title>NIK-333(Peretinoin)</title>
          <description>NIK-333(peretinoin): 600mg (8 x 75mg capsules) orally, twice a day</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo: Placebo (8 x Placebo capsules) orally, twice a day</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="301"/>
            <count group_id="B2" value="304"/>
            <count group_id="B3" value="605"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 65 and 75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="150"/>
                    <measurement group_id="B2" value="136"/>
                    <measurement group_id="B3" value="286"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="123"/>
                    <measurement group_id="B3" value="241"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="183"/>
                    <measurement group_id="B2" value="181"/>
                    <measurement group_id="B3" value="364"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Recurrence-free Survival</title>
        <description>HCC recurrence was defined as the appearance of new intrahepatic lesions which was confirmed based on findings of hypervascularity (nodules enhanced in the arterial phase and washout in the late phase) by dynamic CT images, or a new extrahepatic metastasis. Recurrence of intrahepatic HCC was evaluated by an independent image reading committee.&#xD;
RFS was defined as the time from randomization to HCC recurrence or death from any cause, whichever occurred first. For subjects who terminated the study without HCC recurrence or death, RFS was censored at the day of the latest dynamic CT examination.</description>
        <time_frame>Date of randomization to the date of recurrence of HCC (followed every 12 weeks) or death (whichever occurs first)</time_frame>
        <population>Full analysis set (FAS) consisted of 605 subjects among 616 randomized subjects. Reasons for 11 excluded subjects are as following;&#xD;
6 Subjects (NIK-333 group: 4, Placebo group: 2) who did not take any study drugs&#xD;
5 Subjects (NIK-333 group: 4, Placebo group: 1) who had no efficacy data</population>
        <group_list>
          <group group_id="O1">
            <title>NIK-333(Peretinoin)</title>
            <description>NIK-333(peretinoin): 600mg (8 x 75mg capsules) orally, twice a day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Placebo (8 x Placebo capsules) orally, twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Recurrence-free Survival</title>
          <description>HCC recurrence was defined as the appearance of new intrahepatic lesions which was confirmed based on findings of hypervascularity (nodules enhanced in the arterial phase and washout in the late phase) by dynamic CT images, or a new extrahepatic metastasis. Recurrence of intrahepatic HCC was evaluated by an independent image reading committee.&#xD;
RFS was defined as the time from randomization to HCC recurrence or death from any cause, whichever occurred first. For subjects who terminated the study without HCC recurrence or death, RFS was censored at the day of the latest dynamic CT examination.</description>
          <population>Full analysis set (FAS) consisted of 605 subjects among 616 randomized subjects. Reasons for 11 excluded subjects are as following;&#xD;
6 Subjects (NIK-333 group: 4, Placebo group: 2) who did not take any study drugs&#xD;
5 Subjects (NIK-333 group: 4, Placebo group: 1) who had no efficacy data</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="301"/>
                <count group_id="O2" value="304"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="809.0" lower_limit="650.0" upper_limit="1026.0"/>
                    <measurement group_id="O2" value="751.0" lower_limit="600.0" upper_limit="928.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.351</p_value>
            <p_value_desc>A two-sided significance level was set at 0.05. Adjustment of multiplicity considering interim analysis is conducted by the Lan DeMets' method of α consumption function.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.900</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.720</ci_lower_limit>
            <ci_upper_limit>1.124</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease-free Survival</title>
        <description>DFS was defined as the time from randomization to HCC recurrence, death from any cause or occurrence of secondary cancer (malignant tumors other than HCC), whichever occurred first. For subjects who terminated the study without HCC recurrence, death, or occurrence of secondary cancer, DFS was censored at the day of the latest dynamic CT examination.</description>
        <time_frame>Date of randomization to the date of recurrence of HCC (followed every 12 weeks), death, or secondary cancer (malignant tumors other than HCC)(whichever occurs first)</time_frame>
        <population>Full analysis set (FAS) consisted of 605 subjects among 616 randomized subjects. Reasons for 11 excluded subjects are as following;&#xD;
6 Subjects (NIK-333 group: 4, Placebo group: 2) who did not take any study drugs&#xD;
5 Subjects (NIK-333 group: 4, Placebo group: 1) who had no efficacy data</population>
        <group_list>
          <group group_id="O1">
            <title>NIK-333(Peretinoin)</title>
            <description>NIK-333(peretinoin): 600mg (8 x 75mg capsules) orally, twice a day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Placebo (8 x Placebo capsules) orally, twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Disease-free Survival</title>
          <description>DFS was defined as the time from randomization to HCC recurrence, death from any cause or occurrence of secondary cancer (malignant tumors other than HCC), whichever occurred first. For subjects who terminated the study without HCC recurrence, death, or occurrence of secondary cancer, DFS was censored at the day of the latest dynamic CT examination.</description>
          <population>Full analysis set (FAS) consisted of 605 subjects among 616 randomized subjects. Reasons for 11 excluded subjects are as following;&#xD;
6 Subjects (NIK-333 group: 4, Placebo group: 2) who did not take any study drugs&#xD;
5 Subjects (NIK-333 group: 4, Placebo group: 1) who had no efficacy data</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="301"/>
                <count group_id="O2" value="304"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="686.0" lower_limit="532.0" upper_limit="860.0"/>
                    <measurement group_id="O2" value="642.0" lower_limit="528.0" upper_limit="771.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.222</p_value>
            <p_value_desc>A two-sided significance level was set at 0.05.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.875</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.706</ci_lower_limit>
            <ci_upper_limit>1.085</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Recurrence</title>
        <description>TTR was defined as the time from randomization to HCC recurrence. For subjects who terminated the study without HCC recurrence, TTR was censored at the day of the latest dynamic CT examination.</description>
        <time_frame>Date of randomization to the date of recurrence of HCC(followed every 12 weeks)</time_frame>
        <population>Full analysis set (FAS) consisted of 605 subjects among 616 randomized subjects. Reasons for 11 excluded subjects are as following;&#xD;
6 Subjects (NIK-333 group: 4, Placebo group: 2) who did not take any study drugs&#xD;
5 Subjects (NIK-333 group: 4, Placebo group: 1) who had no efficacy data</population>
        <group_list>
          <group group_id="O1">
            <title>NIK-333(Peretinoin)</title>
            <description>NIK-333(peretinoin): 600mg (8 x 75mg capsules) orally, twice a day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Placebo (8 x Placebo capsules) orally, twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Recurrence</title>
          <description>TTR was defined as the time from randomization to HCC recurrence. For subjects who terminated the study without HCC recurrence, TTR was censored at the day of the latest dynamic CT examination.</description>
          <population>Full analysis set (FAS) consisted of 605 subjects among 616 randomized subjects. Reasons for 11 excluded subjects are as following;&#xD;
6 Subjects (NIK-333 group: 4, Placebo group: 2) who did not take any study drugs&#xD;
5 Subjects (NIK-333 group: 4, Placebo group: 1) who had no efficacy data</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="301"/>
                <count group_id="O2" value="304"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="842.0" lower_limit="673.0" upper_limit="1094.0"/>
                    <measurement group_id="O2" value="764.0" lower_limit="608.0" upper_limit="936.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.279</p_value>
            <p_value_desc>A two-sided significance level was set at 0.05.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.882</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.703</ci_lower_limit>
            <ci_upper_limit>1.108</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the starting day of study drug administration to 35 days after the discontinuation of the study drug administration, up to approximately 4.3 years.</time_frame>
      <desc>Safety analysis set consisted of 610 subjects who received treatment. Since the number of SAE of HCC recurrence is larger than other SAEs and is greater in the Placebo group than in NIK-333 group, we consider that there is a concern of underestimating the safety issue from the following points.&#xD;
It becomes difficult to understand what extent SAE that pose a safety concern have occurred.&#xD;
The incidence of SAE in placebo group and NIK-333 group appears to be similar.</desc>
      <group_list>
        <group group_id="E1">
          <title>NIK-333(Peretinoin)</title>
          <description>NIK-333(peretinoin): 600mg (8 x 75mg capsules) orally, twice a day</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo: Placebo (8 x Placebo capsules) orally, twice a day</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="222" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="223" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Meniere's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Sudden hearing loss</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blepharochalasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="305"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Macular fibrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="305"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Gastric polyps</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Oesophageal varices haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Periodontal disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Gastric varices</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Gastric antral vascular ectasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="305"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Large intestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Varices oesophageal</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="305"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Gastric varices haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Intestinal varices</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="305"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Drowning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Performance status decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Implant site haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Disuse syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Hepatorenal syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Portal vein thrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Abscess neck</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Infected cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Enteritis infectious</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Extradural haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Heat illness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Traumatic haemothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="305"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Polymyalgia rheumatica</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Bile duct cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Diffuse large B-cell lymphoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Gastric cancer stage 0</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Gastric cancer stage I</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="305"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of lung</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Gastric adenoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Oesophageal squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Extranodal marginal zone B-cell lymphoma (MALT type)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Hepatocellular carcinoma</sub_title>
                <counts group_id="E1" events="131" subjects_affected="131" subjects_at_risk="305"/>
                <counts group_id="E2" events="171" subjects_affected="171" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Autonomic nervous system imbalance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Cerebellar haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="305"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Glomerulonephritis membranous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Diabetic nephropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhage subcutaneous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Stasis dermatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Aortic thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Peripheral artery aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="253" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="193" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="42" subjects_affected="41" subjects_at_risk="305"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="39" subjects_affected="35" subjects_at_risk="305"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="41" subjects_affected="34" subjects_at_risk="305"/>
                <counts group_id="E2" events="32" subjects_affected="28" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="305"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="42" subjects_affected="40" subjects_at_risk="305"/>
                <counts group_id="E2" events="26" subjects_affected="22" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="25" subjects_affected="21" subjects_at_risk="305"/>
                <counts group_id="E2" events="17" subjects_affected="16" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="305"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="45" subjects_affected="32" subjects_at_risk="305"/>
                <counts group_id="E2" events="20" subjects_affected="14" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="167" subjects_affected="109" subjects_at_risk="305"/>
                <counts group_id="E2" events="187" subjects_affected="99" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="27" subjects_affected="25" subjects_at_risk="305"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Albumin urine present</sub_title>
                <counts group_id="E1" events="22" subjects_affected="21" subjects_at_risk="305"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="305"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="20" subjects_affected="18" subjects_at_risk="305"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="40" subjects_affected="38" subjects_at_risk="305"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="305"/>
                <counts group_id="E2" events="18" subjects_affected="16" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="305"/>
                <counts group_id="E2" events="23" subjects_affected="18" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="305"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="305"/>
                <counts group_id="E2" events="27" subjects_affected="17" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Nail disorder</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="305"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="29" subjects_affected="27" subjects_at_risk="305"/>
                <counts group_id="E2" events="38" subjects_affected="33" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="305"/>
                <counts group_id="E2" events="16" subjects_affected="13" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="100" subjects_affected="95" subjects_at_risk="305"/>
                <counts group_id="E2" events="31" subjects_affected="30" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Administrator of clinical trial information</name_or_title>
      <organization>Pharmaceutical Division, Clinical Administration Dept.</organization>
      <email>ctrdinfo@kowa.co.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

